M A Perera
Overview
Explore the profile of M A Perera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hepatocyte gene expression and DNA methylation as ancestry-dependent mechanisms in African Americans
Park C, De T, Xu Y, Zhong Y, Smithberger E, Alarcon C, et al.
NPJ Genom Med
. 2019 Dec;
4:29.
PMID: 31798965
African Americans (AAs) are an admixed population with widely varying proportion of West African ancestry (WAA). Here we report the correlation of WAA to gene expression and DNA methylation in...
2.
Johnson J, Caudle K, Gong L, Whirl-Carrillo M, Stein C, Scott S, et al.
Clin Pharmacol Ther
. 2017 Feb;
102(3):397-404.
PMID: 28198005
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for...
3.
Hernandez W, Gamazon E, Aquino-Michaels K, Smithberger E, OBrien T, Harralson A, et al.
J Thromb Haemost
. 2017 Jan;
15(4):735-743.
PMID: 28135054
Summary: Background Warfarin is commonly used to control and prevent thromboembolic disorders. However, because of warfarin's complex dose-requirement relationship, safe and effective use is challenging. Pharmacogenomics-guided warfarin dosing algorithms that...
4.
Chang S, McDonough C, Gong Y, Johnson T, Tsunoda T, Gamazon E, et al.
Pharmacogenomics J
. 2016 Sep;
18(1):106-112.
PMID: 27670767
We conducted a discovery genome-wide association study with expression quantitative trait loci (eQTL) annotation of new-onset diabetes (NOD) among European Americans, who were exposed to a calcium channel blocker-based strategy...
5.
Kubo K, Ohara M, Tachikawa M, Cavallari L, Lee M, Wen M, et al.
Pharmacogenomics J
. 2016 Aug;
17(6):494-500.
PMID: 27503578
Using population pharmacokinetic analysis (PPK), we attempted to identify predictors of S-warfarin clearance (CL(S)) and to clarify population differences in S-warfarin pharmacokinetics among a cohort of 378 African American, Asian...
6.
Perera M, Cavallari L, Johnson J
Clin Pharmacol Ther
. 2014 Feb;
95(3):242-4.
PMID: 24548987
No abstract available.
7.
Hernandez W, Gamazon E, Aquino-Michaels K, Patel S, OBrien T, Harralson A, et al.
Pharmacogenomics J
. 2013 Sep;
14(3):223-8.
PMID: 24018621
Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs)....
8.
Perera M, Gamazon E, Cavallari L, Patel S, Poindexter S, Kittles R, et al.
Clin Pharmacol Ther
. 2011 Jan;
89(3):408-15.
PMID: 21270790
It is well recognized that the genetic variants VKORC1-1639, CYP2C9*2, and CYP2C9*3 contribute to warfarin dose response. This has led to warfarin dosing algorithms that include these polymorphisms and explains...
9.
Perera M, Thirumaran R, Cox N, Hanauer S, Das S, Brimer-Cline C, et al.
Pharmacogenomics J
. 2008 Oct;
9(1):49-60.
PMID: 18825162
The CYP3A locus encodes hepatic enzymes that metabolize many clinically used drugs. However, there is marked interindividual variability in enzyme expression and clearance of drugs metabolized by these enzymes. We...
10.
Perera M, Harischandra P, Wimalaratne O, Damboragama S
Ceylon Med J
. 2000 Oct;
45(2):61-4.
PMID: 11051702
Objective: To test the feasibility of introducing oral rabies vaccine (vaccinia recombinant rabies glycoprotein) to improve domestic dog immunisation coverage in a selected area. Design: A prospective field trial. Setting:...